|Mr. Dilip Shantilal Shanghvi||MD & Exec. Director||43.08M||N/A||1955|
|Mr. C. S. Muralidharan||Chief Financial Officer||38.89M||N/A||1963|
|Mr. Sailesh Trambaklal Desai||Whole Time Director||15.81M||N/A||1954|
|Mr. Kalyanasundaram Subramanian||CEO of India Bus. and Emerging Markets & Whole-Time Director||49.74M||N/A||1954|
|Mr. Sunil R. Ajmera||Company Sec.||14.01M||N/A||N/A|
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers formulations in various therapeutic areas, including central nervous system, dermatology, cardiology, oncology and ophthalmic, neuro-psychiatry, gastroenterology, anti-infectives, diabetology, pain/analgesics, vitamins/minerals/nutrients, respiratory, gynaecology, urology, opthalomology, orthopaedic, nephrology, dental, and other areas. It also provides APIs for anti-cancers, peptides, steroids, sex hormones, and controlled substances, as well as over-the-counter products. Sun Pharmaceutical Industries Limited was founded in 1983 and is based in Mumbai, India.
Sun Pharmaceutical Industries Limited’s ISS Governance QualityScore as of December 8, 2019 is 10. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 5; Compensation: 9.